SEARCH

SEARCH BY CITATION

References

  • 1
    Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001;17: 982994.
  • 2
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; NIH Publication No. 2701: 1–100.
  • 3
    Rabe KF, Hurd S, Anzueto A, et al.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532555.
  • 4
    Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med. 2012. Epub ahead of Print.
  • 5
    Lange P, Rasmussen FV, Borgeskov H, Dollerup J, Jensen MS, Roslind K, Nielsen LM. The quality of COPD care in general practice in Denmark: the KVASIMODO study. Prim Care Respir J. 2007;16: 174181.
  • 6
    Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100: 115122.
  • 7
    Vestbo J, Rodriguez-Roisin R. GOLD and the fixed ratio. Eur Respir J. 2011;38: 481482.
  • 8
    Hoesein FAAM, Zanen P, Lammers J-WJ. Lower limit of normal or FEV1/FVC <0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011;105: 907915.
  • 9
    Ulrik CS, Løkke A, Dahl R, Dollerup J, Hansen G, Cording PH, Andersen KK. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis. 2011;6: 123127.
  • 10
    Bakke PS, Rönmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD. ERS task force report. Eur Respir J. 2011;38: 12611277.
  • 11
    Hurst JR, Vestbo J, Anzueto A, et al.; for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363: 11281138.
  • 12
    Soler-Cataluna JJ, Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious? COPD. 2010;7: 276284.
  • 13
    Eriksen N, Vestbo J. Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. Clin Respir J. 2010;4: 208214.
  • 14
    Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011;66: 585590.
  • 15
    Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(10)Art. No.: CD005305. DOI: 10.1002/14651858.CD005305.pub3.
  • 16
    Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370: 786796.
  • 17
    Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341: c5462.
  • 18
    Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ. 2003;326: 185.
  • 19
    Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128: 20992107.
  • 20
    Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32: 962969.
  • 21
    Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28: 12451257.
  • 22
    Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21: 10121016.
  • 23
    Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population-based database study. Clin Respir J. 2010;4: 2229.
  • 24
    Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EFM, Rennard SI, Sharafkhaneh A, on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183: 604611.
  • 25
    Hawkins NM, Jhund PS, Simpson CR, Petrie MC, MacDonald MR, Dunn FG, MacIntyre K, McMurray JJV. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail. 2010;12: 1724.
  • 26
    Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4): CD003566.
  • 27
    Short PM, Lipworth SIW, Elder DHJ, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342: d2549.